GenTrust LLC Decreases Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

GenTrust LLC trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 72.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,044 shares of the company’s stock after selling 5,265 shares during the period. GenTrust LLC’s holdings in Novo Nordisk A/S were worth $243,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of the company. BOKF NA grew its position in Novo Nordisk A/S by 31.6% in the 1st quarter. BOKF NA now owns 7,792 shares of the company’s stock valued at $994,000 after acquiring an additional 1,871 shares during the last quarter. Ascent Group LLC grew its position in Novo Nordisk A/S by 4.3% in the 1st quarter. Ascent Group LLC now owns 19,199 shares of the company’s stock valued at $2,465,000 after acquiring an additional 795 shares during the last quarter. Captrust Financial Advisors grew its position in Novo Nordisk A/S by 3.4% in the 1st quarter. Captrust Financial Advisors now owns 149,826 shares of the company’s stock valued at $19,238,000 after acquiring an additional 4,947 shares during the last quarter. Silvercrest Asset Management Group LLC grew its position in Novo Nordisk A/S by 9.0% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 134,060 shares of the company’s stock valued at $17,213,000 after acquiring an additional 11,020 shares during the last quarter. Finally, Iron Gate Global Advisors LLC grew its position in Novo Nordisk A/S by 9.7% in the 1st quarter. Iron Gate Global Advisors LLC now owns 2,410 shares of the company’s stock valued at $307,000 after acquiring an additional 214 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Trading Up 2.4 %

Shares of NYSE:NVO opened at $105.06 on Friday. Novo Nordisk A/S has a 52-week low of $94.73 and a 52-week high of $148.15. The stock has a market cap of $471.46 billion, a price-to-earnings ratio of 34.00, a PEG ratio of 1.32 and a beta of 0.42. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The business has a 50-day moving average price of $115.48 and a 200-day moving average price of $128.80.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.